Original Research
Copyright ©The Author(s) 2001. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 15, 2001; 7(5): 667-671
Published online Oct 15, 2001. doi: 10.3748/wjg.v7.i5.667
Effect of cholecystokinin on cytokines during endotoxic shock in rats
Yi-Ling Ling, Ai-Hong Meng, Xiao-Yun Zhao, Bao-En Shan, Jun-Lan Zhang, Xiao-Peng Zhang
Yi-Ling Ling, Ai-Hong Meng, Xiao-Yun Zhao, Jun-Lan Zhang, Department of Pathophysiology, Hebei Medical University, Shijiazhuang 050017, Hebei Province, China
Bao-En Shan, Research Center of Fourth Hospital, Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Xiao-Peng Zhang, Department of Chest Surgery of Hebei Provincial People’s Hospital, Shijiazhuang 050000, Hebei Province, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Professor Yi-Ling Ling, Department of Pathophysiology, Hebei Medical University, Shijiazhuang 050017, Hebei Province, China. LingYL20@sina.com.cn
Telephone: +86-311-6052263
Received: June 3, 2001
Revised: August 6, 2001
Accepted: August 20, 2001
Published online: October 15, 2001

Abstract

AIM: To study the effect of cholecystokinin-octapeptide (CCK-8) on systemic hypotension and cytokine production in lipopolysaccharide (LPS)-induced endotoxic shock (ES) rats.

METHODS: The changes of blood pressure were observed using physiological record instrument in four groups of rats: LPS (8 mg•kg¯¹, iv) induced ES; CCK-8 (40 μg•kg¯¹, iv) pretreatment 10 min before LPS (8 mg•kg¯¹); CCK-8 (40 μg•kg¯¹, iv) or normal saline (control) groups. Differences in tissue and circulating specificity of the proinflammatory cytokines (TNF-α, IL-1β and IL-6) were assayed with ELISA kits.

RESULTS: CCK-8 reversed LPS-induced decrease of mean artery blood pressure (MABP) in rats. Compared with control, LPS elevated the serum level of IL-6 significantly (3567 ± 687) ng•L¯¹vs 128 ± 22 ng•L¯¹, P < 0.01), while contents of TNF-αβ elevated significantly (277 ± 86 ng•L¯¹vs not detectable and 43 ± 9 ng•L¯¹vs not detectable, P < 0.01) but less extent than IL-6. CCK-8 significantly inhibited the LPS-induced increase in serum TNF-α, IL-1β and IL-6. LPS elevated spleen and lung content of IL-1β significantly (5184 ± 85 ng•L¯¹vs 1047 ± 21 ng•L¯¹ and 4050 ± 614 ng•L¯¹vs not detectable, P < 0.01), while levels of TNF-α and IL-6 also rose significantly but in less extent than IL-1β. CCK-8 inhibited the LPS-induced increase of the cytokines in spleen and lung. In the heart, CCK-8 significantly inhibited LPS-induced increase of TNF-α (864 ± 123 ng•L¯¹ in CCK-8 + LPS group vs 1599 ± 227 ng•L¯¹ in LPS group, P < 0.01), and IL-1β (282 ± 93 ng•L¯¹ in CCK-8+LPS group vs 621 ± 145 ng•L¯¹ in LPS group, P < 0.01).

CONCLUSION: CCK-8 reverses ES, which may be related to its inhibitory effect on the overproduction of cytokines.

Key Words: sincalide/pharmacology, lipopolysaccharides, shock, septic/drug therapy, shock, septic/blood, tumor necrosis factor/analysis, interleukins/blood, hypotension/drug therapy, hypotension/etiology



INTRODUCTION

Lipopolysaccharide (LPS), a main component of gram-negative bacterial endotoxin [1], is the leading cause of sepsis or endotoxic shock (ES), and when administered experimentally to animals, mimics the same inflammatory response. The pathophysiological changes seen in sepsis are often not due to the infectious organism itself but to the uncontrolled production of proinflammatory cytokine s, including tumor necrosis factor (TNF)-α and interleukin (IL)-1β. Accumulation of these mediators leads to tissue damage, ultimately producing the lethality of sepsis[2]. Studies suggest that alterations in their circulating levels do not always reflect changes at the tissue level and this has led to the reassessment of tissue cytokine content as a more accurate reflection of the host response to stress[3]. Cholecystokinin (CCK), a component of the gastrin-CCK family and first isolated from hog intestine, shows a widespread distribution in different organs and tissues. The sulfated carboxy-terminal octapeptide (CCK-8), which has been isolated from the central nervous system and digestive tract, is the predominant active form. CCK-8 possessed both excitatory and inhibitory action on contractile activity of different regions of stomach in guinea pigs[4]. CCK-8 could antagonize the elimination of morphine on the potentiations of ACh to duodenal activities, and these effects were mediated by CCK-A receptor[5]. Besides the effects of CCK-8 on the digestive tract, other biological actions of this peptide have been observed, such as appetite inhibition[6,7]. In the spleen, CCK-8 is formed in high abundance in the white pulp where it appears to surround cell clusters. It seems that CCK -8 increases in vivo the secretion of immunoglobulins[8,9], while it causes in vitro an inhibition of Molt-4 lymphoblast proliferation[10] and modulates mitogen-induced lymphoproliferation and intracellular calcium mobilization[11-13]. CCK-8 is a chemoattractant for human monocytes and rat macrophages[14], enhances human eosinophil chemotaxis induced by PAF and LTB4 in allergic patients[15] and is a negative modulator of several murine macrophage and human neutrophil functions[16-18]. It was reported that CCK-8 reversed hemorrhagic shock[19,20]. Our previous studies demonstrated for the first time that CCK-8 could protect animals from LPS-induced ES[21]. However, whether this protecting effect of CCK-8 is related to its modulation of cytokines is still not clear. The AIM of this work is to study the effect of CCK-8 pretreatment on systemic hypotension and on production of cytokines such as TNF-α, IL- 1β and IL-6 in spleen, lung, heart and serum of ES rats.

MATERIALS AND METHODS
Materials

CCK-8 (sulfated), LPS (E. coli LPS, serotype 0111:B4), leupeptin, pepstatin A and Triton X-100 were all purchased from Sigma and aprotinin from Boehringer. ELISA kits were purchased from Endogen (USA) and Medsystem (Austria). All other reagents used were of analytic grade.

METHODS

Animal preparation Specific pathogen-free male Sprague-Daw ley rats (n = 48, weighing 150 g-200 g, obtained from Experimental Animal Center of Hebei) were housed in a controlled environment, exposed to 12 h:12 h light-dark cycle and fed standard rat diet. On the day of experiment, animals were randomly assigned to four groups injected different agents via tail vein. For group receiving LPS, a bolus dose (8 mg•kg¯¹, 5 g•L¯¹) of LPS was injected into the tail vein. For group of CCK-8+LPS, a bolus dose (40 μg•kg¯¹, 0.05 g•L¯¹) of CCK-8 was administered 10 min before injection of LPS. Negative control animals received saline, CCK-8 (40 μg•kg¯¹) was also administe red alone in the other group.

Mean arterial blood pressure (MABP) detection Catheter was inserted into arteriae femoralis before agents administration and MABP was detected using physiology record instrument (RM-6000, Japan). ES model was made by LPS administration, the effect of CCK-8 on MABP of ES rats was observed.

Enzyme linked immunoabsorbant assay (ELISA) Animals were sacrificed at 2 h or 6 h after treated with LPS, spleen, lung and heart were rapidly excised, rinsed of blood, and the blood was centrifuged for collection of serum. The samples were stored at -80 °C. The samples collected at 2 h were for the assay of TNF-α and at 6 h for the assay of IL-1β and IL-6. Serum TNF-α was measured using an ELISA kit (Bender MedSystem, Austria) specific for rat TNF-α with an inter-assay coefficient of variation to be < 10% and intra-assay coefficient of variation to be < 5%; the lowest limit of detection was 17 ng•L¯¹. Serum IL-1β was determined with a rat ELISA (Endogen Inc, USA). Intra- and inter-assay coefficients of variation were 5.3%-6.1% and 6.8%-8.8%, respectively. The limit of detection for this assay was < 12 ng•L¯¹. Serum IL-6 was determined with a rat ELISA (Endogen Inc, USA). The intra and inter-assay coefficients of variation were 8.3%-9.2% and 6.9%-7.8%, respectively. The lowest limit of detection was 16 ng•L¯¹.

Forzen tissue samples were weighed and placed in homogenization buffer (4 °C) at a ratio of 100 mg per milliliter of buffer. Buffer contained a protease-inhibitor cocktail including 1 mmol•L¯¹ phenylmethanesulfonyl fluoride (PMSF), 1 mg•L¯¹ pepstatin A, 1 mg•L¯¹ aprotinin, and 1 mg•L¯¹ leupeptin in phosphate-buffered saline solution, pH7.2, containing 5 g•L¯¹ Triton X-100. Samples were homogenized and centrifuged at 18000 r•min¯¹. Tissue supernatants were analyzed for TNF-α, IL-1β and IL-6 using the above described ELISAs.

Statistical analysis

Data were reported as ¯x ± s. Statistical differences between values from different groups were determined by one way ANOVA. Significance was set at P < 0.05.

RESULTS
Changes of MABP

There was no significant difference among groups before treatment. LPS administration resulted in a significant sustained decrease in MABP during the period of 2 h, decreased to 7.82 ± 0.43 kPa 30 min after LPS administration and restored to 9.33 ± 0.63 kPa by pretreatment with CCK-8 (Figure 1).

Figure 1
Figure 1 Mean arterial blood pressure (MABP) of animals injected normal saline, LPS, CCK+LPS and CCK. n = 6, aP < 0.05, bP < 0.01, vs Control; cP < 0.05, dP < 0.01, vs LPS.
Serum cytokine levels

TNF-α and IL-1β were not detectable in the serum of saline or CCK-8 treated rats, while IL-6 concentration in serum of saline or CCK-8 treated rats were 128 ± 22 ng•L¯¹ and 84 ± 78 ng•L¯¹, respectively. Significant increase in serum level of TNF-α was observed in LPS group at 2 h to an average of 277 ± 86 ng•L¯¹, which was inhibited by CCK-8 to 12 ± 21 ng•L¯¹. Serum levels of IL-1β and IL-6 increased to 43 ± 9 ng•L¯¹ and 3567 ± 687 ng•L¯¹, respectively, 6 h after administration of LPS, while administration of CCK-8 prior to LPS significantly inhibited this LPS induced increase in IL-1β and IL-6 concentration (not detectable and to 1797 ± 69 ng•L¯¹, respectively. LPS elevated the serum level of IL-6 significantly, while serum levels of TNF-α and IL-1β rose significantly but less than IL-6 (Figure 2).

Figure 2
Figure 2 Effects of CCK on TNF-α, IL-1β and IL-6 2 h (TNF-α) or 6 h (IL-1β and IL-6) following LPS administration. n = 6. aP < 0.05, bP < 0.01, vs Control; cP < 0.05, dP < 0.01, vs LPS.
Tissue cytokine contents

Spleen TNF-α content was significantly higher 2 h after administration of LPS than in control animals 941 ± 149 ng•L¯¹vs 282 ± 30 ng•L¯¹, P < 0.01, while CCK-8 significantly inhibited the LPS induced increase of TNF-α 462 ± 87 ng•L¯¹, P < 0.01. Similar results of TNF-α were noted in the lung and heart following 2 h post-LPS administration. CCK-8 pretreatment attenuated LPS-induced increases of IL-1β and IL-6 contents in spleen and lung 6 h after LPS administration. LPS elevated content of IL-1β in the spleen and lung significantly 5184 ± 85 ng•L¯¹vs 1047 ± 21 ng•L¯¹ and 4050 ± 614 ng•L¯¹ vs not detectable, respectively (Figure 2), while the levels of TNF-α and IL-6 rose but in less extent than IL-1β. CCK-8 pretreatment attenuated LPS-induced increases of IL-1β content in the heart 6 h after LPS administration from 621 ± 145 ng•L¯¹ to 282 ± 93 ng•L¯¹, P < 0.01. No significant changes were noted in contents of cytokines following CCK-8 administration compared with normal saline administration.

DISCUSSION

Interaction of the central nervous system (CNS) with immune system can occur via several endocrine pathways, the presence of various neuropeptide receptors on cells of the immune system suggests more direct communication pathways. Moreover, immune cells release cytokines, which can influence neuronal activity. Thus direct communication between the CNS and the immune system may well be bi-directional[22]. The present study show that administration of brain- gut peptide, CCK-8, prevents the LPS-induced decrease of MABP and attenuates LPS-induced increase of proinflammatory cytokines (TNF-α, IL-1β and IL-6) in vivo. Inhibition of these cytokines by CCK-8 may have contributed to the prevention of ES, such as restoring the blood pressure. The macrophages are the sources of proinflammatory cytokines (TNF-α, IL-1 and IL-6)[23]. These three important proinflammatory cytokines respond to the initial stimulation[24] and play predominant roles in the normal inflammatory response. Exaggerated endogenous production is likely responsible for the complications associated with sepsis such as tissue injury and ultimate organ failure[25-28], induce a wide range of pathophysiologic changes in LPS-induced ES. TNF is known to have cytotoxic and cytostatic effects on certain tumor cells, and with a pivotal role in inflammatory reactions and regulation of immunologic al response[29,30]. TNF can enhance the adhesion of PMN to endothelium[31]. Although the migration of leukocytes to and accumulation at the site of inflammation are important for killing micro-organisms, activation of recruited neutrophils coupled with excessive release of oxygen metabolites and proinflammatory mediators may induce tissue injury which can lead to organ dysfunction[32]. TNF-α was mainly produced in the early stage of endotoxemia, and decreased obviously from 6 h to 9 h after challenge[33]. The effect of TNF-α is influenced by other cytokines[34]. IL-1β and IL-6, produced mainly by activated phagocytes and lymphocytes, show a wide variety of biological functions. They can influence secretion of other cytokines and inflammatory mediators in an autocrine or paracrine fashion, induce expression of surface immune molecules of antigen-presenting cells to serve as an activation factor and differentiation factor on T cells and B cells, mediate immunoglobulin secretion, activate the complements, killer cells and phagocytes, and enhance tissue injury mediated by cellular and humoral immune reactions[35]. Most of our knowledge concerning the induction of these cytokines in response to LPS or gram-negative bacteria comes from studies performed either in vitro or in fluids obtained from animal models or patients with sepsis, whereas the major site of action of the cytokines are probably at the tissue and cell level[36]. Our study show that the increase in spleen and lung content of IL-6 following LPS administration was lesser than in serum. In contrast, the increase in spleen and lung content of IL-1β following LPS administration was more than in serum, while the content of IL-1β in heart was more than in serum and less than in spleen and lung. The results demonstrated a dissociation or poor correlation between intra -splenic, intra-pulmonic or intra-cardiac abundance of TNF-α, IL-1β and IL-6 and the magnitude of the increase in circulating cytokine levels. The production of cytokines varies from organ to organ in response to systemic administration of LPS. Activated macrophages in spleen and lung are known to be active producers of pro-inflammatory cytokines. This has led to the suggestion that spleen, lung and heart are important organs in the production of TNF-α and IL-1β following LPS administration, releasing the cytokines produced into the circulation, thereby contributing to the elevated serum levels of the cytokines. We found that CCK-8 significantly inhibits LPS-induced increase of pro-inflammatory cytokines in vivo. While Cunningham et al[37] reported that CCK-8 stimulated production of TNF-α, IL-1β and IL-6 by monocytes, but was considerably less than LPS response. Later studies[38] suggest that the increase of cytokines induced by CCK-8 may be due to the detection of endotoxin/LPS in medium.

Despite convincing data indicating the protective function of CCK-8 to organism in ES, the precise mechanism remains elusive. Our previous study demons trated that exogenous or endogenous CCK reversed pulmonary arterial hypertension (PAH) during endotoxic shock[39]. In vitro studies showed CCK can protect pulmonary artery endothelium against detrimental effects by LPS or TNF-α[40,41]. The anti-inflammatory effect of CCK- showed in this study may mediate the cell protective function of CCK-8 in ES. CCK-8 dose dependently attenuated gastric lesions induced by 75% ethanol, blockade of CCKA receptor with loxiglumide abolished the protective effects of CCK[42]. The effect of CCK may depend on its modulation of immunocyte function, which could occur through CCK receptors. There exists CCKB receptor in human lymphoid cells[43]. It was demonstrated recently that wild-type transcripts of both CCK receptor subtypes and splice variants of the CCK-B/gastrin receptor are expressed in nontransformed human mononuclear cells[44]. Endogenous opioids, such as β-endorphin, are produced within the immune system and are active regulators of the immune response. There were elevations in the circulating levels of β-endorphin in LPS-treated animals, which indicated the potential contribution to modulating the tissue cytokine response to LPS[45]. The hypotensive response was related to release of endorphin, while the mechanism of CCK-8 anti-ES may be related to its anti-endorphin effect[3]. CCK-8 decreased heart rate via CCK-A receptors located in the atrium of the rats[46]. Intravenous administration of CCK-8 to guinea pigs inhibited the motility of the left ventricle of heart[47]. CCK had hypertensive effect on rats and increased the cardiac contraction amplitude, decreased coronary outflow, while it had no effect on heart rate[48]. CCK-B agonist pentagastrin induced significant and very rapid, dose-dependent elevations in adrenocorticotropin and cortisol levels, and significant elevations in heart rate and blood pressure were seen[49]. The different effect of CCK-8 on cardiovascular system may due to the different doses and animals. However, additional mechanisms may be present in mediating the cytokine responses to LPS and CCK. Our study shows for the first time a previously unknown physiological function for CCK- 8 in a model of LPS-induced ES. CCK-8 may have modulatory effects on the immune functions of ES rats. CCK-8, therefore, might be used therapeutically to treat septic shock syndrome and other inflammatory disease states.

Footnotes

Edited by Ma JY

References
1.  Fan K. Regulatory effects of lipopolysaccharide in murine macrophage proliferation. World J Gastroenterol. 1998;4:137-139.  [PubMed]  [DOI]
2.  Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, Choi AM. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med. 2000;6:422-428.  [PubMed]  [DOI]
3.  Molina PE, Abumrad NN. Differential effects of hemorrhage and LPS on tissue TNF-alpha, IL-1 and associate neuro-hormonal and opioid alterations. Life Sci. 2000;66:399-409.  [PubMed]  [DOI]
4.  Li W, Zheng TZ, Qu SY. Effect of cholecystokinin and secretin on contractile activity of isolated gastric muscle strips in guinea pigs. World J Gastroenterol. 2000;6:93-95.  [PubMed]  [DOI]
5.  Xu MY, Lu HM, Wang SZ, Shi WY, Wang XC, Yang DX, Yang CX, Yang LZ. Effect of devazepide reversed antagonism of CCK-8 against morphine on electrical and mechanical activities of rat duodenum in vitro. World J Gastroenterol. 1998;4:524-526.  [PubMed]  [DOI]
6.  De la Fuente M, Carrasco M, Del Rio M, Hernanz A. Modulation of murine lymphocyte functions by sulfated cholecystokinin octapeptide. Neuropeptides. 1998;32:225-233.  [PubMed]  [DOI]
7.  Du YP, Zhang YP, Wang SC, Shi J, Wu SH. Function and regulation of cholecystokinin octapeptide, beta-endorphin and gastrin in anorexic infantile rats treated with ErBao Granules. World J Gastroenterol. 2001;7:275-280.  [PubMed]  [DOI]
8.  Trout WE, Pekas JC, Schanbacher BD. Immune, growth and carcass responses of ram lambs to active immunization against desulfated cholecystokinin (CCK-8). J Anim Sci. 1989;67:2709-2714.  [PubMed]  [DOI]
9.  Alverdy J, Stern E, Poticha S, Baunoch D, Adrian T. Cholecystokinin modulates mucosal immunoglobulin A function. Surgery. 1997;122:386-92; discussion 392-3.  [PubMed]  [DOI]
10.  Tang SC, Braunsteiner H, Wiedermann CJ. Regulation of human T lymphoblast growth by sensory neuropeptides: augmentation of cholecystokinin-induced inhibition of Molt-4 proliferation by somatostatin and vasoactive intestinal peptide in vitro. Immunol Lett. 1992;34:237-242.  [PubMed]  [DOI]
11.  Elitsur Y, Luk GD. The inhibition effect of cholecystokinin in human colonic lamina propria lymphocyte proliferation, and reversal by the cholecystokinin receptor antagonist L-364718. Neuropeptides. 1991;20:41-47.  [PubMed]  [DOI]
12.  Ferrara A, McMillen MA, Schaefer HC, Zucker KA, Goldering JR, Modlin IM. Cholecystokinin mediated calcium signals in peripheral human blood monocytes. FASEB J. 1989;3:A998.  [PubMed]  [DOI]
13.  McMillen MA, Ferrara A, Adrian TE, Margolis DS, Schaefer HC, Zucker KA. Cholecystokinin effect on human lymphocyte ionized calcium and mitogenesis. J Surg Res. 1995;58:149-158.  [PubMed]  [DOI]
14.  Sacerdote P, Ruff MR, Pert CB. Cholecystokinin and the immune system: receptor-mediated chemotaxis of human and rat monocytes. Peptides. 1988;9 Suppl 1:29-34.  [PubMed]  [DOI]
15.  Numao T, Agrawal DK. Neuropeptides modulate human eosinophil chemotaxis. J Immunol. 1992;149:3309-3315.  [PubMed]  [DOI]
16.  De la Fuente M, Campos M, Del Rio M, Hernanz A. Inhibition of murine peritoneal macrophage functions by sulfated cholecystokinin octapeptide. Regul Pept. 1995;55:47-56.  [PubMed]  [DOI]
17.  Carrasco M, Del Rio M, Hernanz A, De la Fuente M. Inhibition of human neutrophil functions by sulfated and nonsulfated cholecystokinin octapeptides. Peptides. 1997;18:415-422.  [PubMed]  [DOI]
18.  De la Fuente M, Medina S, Del Rio M, Ferrández MD, Hernanz A. Effect of aging on the modulation of macrophage functions by neuropeptides. Life Sci. 2000;67:2125-2135.  [PubMed]  [DOI]
19.  Bertolini A, Guarini S, Ferrari W, Rompianesi E. Caerulein and cholecystokinin reverse experimental hemorrhagic shock. Neuropeptides. 1986;8:25-31.  [PubMed]  [DOI]
20.  Guarini S, Bazzani C, Leo L, Bertolini A. Haematological changes induced by the intravenous injection of CCK-8 in rats subjected to haemorrhagic shock. Neuropeptides. 1988;11:69-72.  [PubMed]  [DOI]
21.  Ling YL, Huang SS, Wang LF, Zhang JL, Wan M, Hao RL. [Cholecystokinin-octapeptide (CCK-8) reverses experimental endotoxin shock]. Sheng Li Xue Bao. 1996;48:390-394.  [PubMed]  [DOI]
22.  Li YM, Huang YX. Effect of brain-gut peptide and cellular factors in regulating brain-gut immune mechanism by acupuncture. Shijie Huaren Xiaohua Zazhi. 2001;9:329-332.  [PubMed]  [DOI]
23.  Wu XN. Current concept of pathogenesis of severe acute pancreatitis. World J Gastroenterol. 2000;6:32-36.  [PubMed]  [DOI]
24.  Xia B, Guo HJ, Crusius J, Deng CS, Meuwissen S, Pena A. In vitro production of TNF-alpha, IL-6 and sIL-2R in Chinese patients with ulcerative colitis. World J Gastroenterol. 1998;4:252-255.  [PubMed]  [DOI]
25.  Zhang GQ, Yu H, Zhou XQ, Liao D, Xie Q, Wang B. TNF-α induced apoptosis and necrosis of mice hepatocytes. Shijie Huaren Xiaohua Zazhi. 2000;8:303-306.  [PubMed]  [DOI]
26.  Schlag G, Redl H. Mediators of injury and inflammation. World J Surg. 1996;20:406-410.  [PubMed]  [DOI]
27.  Jansen MJ, Hendriks T, Vogels MT, van der Meer JW, Goris RJ. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Crit Care Med. 1996;24:1196-1202.  [PubMed]  [DOI]
28.  Zhou LS, Shi JS, Wang ZR, Wang L. Tumor necrosis factor-α in gallbladder and gallstone. Shijie Huaren Xiaohua Zazhi. 2000;8:426-428.  [PubMed]  [DOI]
29.  Bai XY, Jia XH, Cheng LZ, Gu YD. Influence of IFN alpha-2b and BCG on the release of TNF and IL-1 by Kupffer cells in rats with hepatoma. World J Gastroenterol. 2001;7:419-421.  [PubMed]  [DOI]
30.  Wu RQ, Xu YX, Song XH, Chen LJ, Meng XJ. Adhesio nmolecule and proinflammatory cytokine gene expression in hepatic sinusoidal endothelial cells following cecal ligation and puncture. World J Gastroenterol. 2001;7:128-130.  [PubMed]  [DOI]
31.  Qin RY, Zou SQ, Wu ZD, Qiu FZ. Experimental research on production and uptake sites of TNFalpha in rats with acute hemorrhagic necrotic pancreatitis. World J Gastroenterol. 1998;4:144-146.  [PubMed]  [DOI]
32.  Wu P, Li X, Zhou T, Zhang MJ, Chen JL, Wang WM, Chen N, Dong DC. Role of P-selectin and anti-P-selectin monoclonal antibody in apoptosis during hepatic/renal ischemia reperfusion injury. World J Gastroenterol. 2000;6:244-247.  [PubMed]  [DOI]
33.  Zang GQ, Zhou XQ, Yu H, Xie Q, Zhao GM, Wang B, Guo Q, Xiang YQ, Liao D. Effect of hepatocyte apoptosis induced by TNF-alpha on acute severe hepatitis in mouse models. World J Gastroenterol. 2000;6:688-692.  [PubMed]  [DOI]
34.  Yu YY, Si CW, Tian XL, He Q, Xue HP. Effect of cytokines on liver necrosis. World J Gastroenterol. 1998;4:311-313.  [PubMed]  [DOI]
35.  Wu HG, Zhou LB, Pan YY, Huang C, Chen HP, Shi Z, Hua XG. Study of the mechanisms of acupuncture and moxibustion treatment for ulcerative colitis rats in view of the gene expression of cytokines. World J Gastroenterol. 1999;5:515-517.  [PubMed]  [DOI]
36.  Ge Y, Ezzell RM, Clark BD, Loiselle PM, Amato SF, Warren HS. Relationship of tissue and cellular interleukin-1 and lipopolysaccharide after endotoxemia and bacteremia. J Infect Dis. 1997;176:1313-1321.  [PubMed]  [DOI]
37.  Cunningham ME, Shaw-Stiffel TA, Bernstein LH, Tinghitella TJ, Claus RE, Brogan DA, McMillen MA. Cholecystokinin-stimulated monocytes produce inflammatory cytokines and eicosanoids. Am J Gastroenterol. 1995;90:621-626.  [PubMed]  [DOI]
38.  Lieb K, Fiebich BL, Busse-Grawitz M, Hüll M, Berger M, Bauer J. Effects of substance P and selected other neuropeptides on the synthesis of interleukin-1 beta and interleukin-6 in human monocytes: a re-examination. J Neuroimmunol. 1996;67:77-81.  [PubMed]  [DOI]
39.  Ling YL, Cong B, Gu ZY, Li SJ, Zhou XH. Inhibitory effect of cholecystokinin octapeptide on pulmonary arterial hypertension during endotoxic shock. Zhongguo Xueshu Qikan Wenzai. 2000;6:890-892.  [PubMed]  [DOI]
40.  Gu ZY, Ling YL, Meng AH, Cong B, Huang SS. Effect of cholecystokinin octapeptide on the response of rabbit pulmonary artery induced by LPS in vitro. Zhongguo Bingli Shengli Zazhi. 1999;15:484-487.  [PubMed]  [DOI]
41.  Meng AH, Ling YL, Wang DH, Gu ZY, Li SJ, Zhu TN. [Cholecystokinin-octapeptide alleviates tumor necrosis factor-alpha induced changes in rabbit pulmonary arterial reactivity and injuries of endothelium in vitro]. Sheng Li Xue Bao. 2000;52:502-506.  [PubMed]  [DOI]
42.  Brzozowski T, Konturek PC, Konturek SJ, Pierzchalski P, Bielanski W, Pajdo R, Drozdowicz D, Kwiecień S, Hahn EG. Central leptin and cholecystokinin in gastroprotection against ethanol-induced damage. Digestion. 2000;62:126-142.  [PubMed]  [DOI]
43.  Cuq P, Gross A, Terraza A, Fourmy D, Clerc P, Dornand J, Magous R. mRNAs encoding CCKB but not CCKA receptors are expressed in human T lymphocytes and Jurkat lymphoblastoid cells. Life Sci. 1997;61:543-555.  [PubMed]  [DOI]
44.  Schmitz F, Schrader H, Otte J, Schmitz H, Stüber E, Herzig K, Schmidt WE. Identification of CCK-B/gastrin receptor splice variants in human peripheral blood mononuclear cells. Regul Pept. 2001;101:25-33.  [PubMed]  [DOI]
45.  Ling YL, Huang SS, Zhang JL, Wan M, Hao RL. Effect of cholecystokinin on SOD, MDA contents and phagocyte chemiluminescence of reversing endotoxin shock rat. Zhongguo Bingli Shengli Zazhi. 1997;13:483-486.  [PubMed]  [DOI]
46.  Kurosawa M, Iijima S, Funakoshi A, Kawanami T, Miyasaka K, Bucinskaite V, Lundeberg T. Cholecystokinin-8 (CCK-8) has no effect on heart rate in rats lacking CCK-A receptors. Peptides. 2001;22:1279-1284.  [PubMed]  [DOI]
47.  Zou S, Zhang J, Qiu F. Influence of octapeptide of cholecystokinin, vasoactive intestinal peptide and substance P on dynamics of biliary system and cardiovascular system. Chin Med J (. Engl). 1998;111:1071-1074.  [PubMed]  [DOI]
48.  Wiśniewska RJ, Wiśniewski K. Involvement of nitric oxide in cardiovascular effects of cholecystokinin (CCK) in rats. Rocz Akad Med Bialymst. 1998;43:169-185.  [PubMed]  [DOI]
49.  Abelson JL, Liberzon I. Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin. Neuropsychopharmacology. 1999;21:485-494.  [PubMed]  [DOI]